Newbury Pharmaceuticals AB (publ) (NEWBRY.ST)
SEK 3.42
(-2.29%)
SEK 3.42
(-2.29%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -15.4 Million SEK | 20.72% |
| 2023 | -19.43 Million SEK | -32.48% |
| 2022 | -14.66 Million SEK | -163.94% |
| 2021 | -5.55 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -4.96 Million SEK | -40.78% |
| 2024 Q1 | -3.52 Million SEK | 25.87% |
| 2024 Q4 | 1.73 Million SEK | 120.07% |
| 2024 Q3 | -8.65 Million SEK | -74.52% |
| 2023 Q1 | - SEK | 0.0% |
| 2023 Q2 | -4.84 Million SEK | 0.0% |
| 2023 FY | -19.43 Million SEK | -32.48% |
| 2023 Q3 | -4.09 Million SEK | 15.45% |
| 2023 Q4 | -4.75 Million SEK | -16.12% |
| 2022 FY | -14.66 Million SEK | -163.94% |
| 2021 FY | -5.55 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | -12.519% |
| AlzeCure Pharma AB (publ) | -37.16 Million SEK | 58.552% |
| BioGaia AB (publ) | 365.35 Million SEK | 104.216% |
| Enzymatica AB (publ) | -49.72 Million SEK | 69.021% |
| Enorama Pharma AB (publ) | -44.61 Million SEK | 65.47% |
| Gabather AB (publ) | -9.43 Million SEK | -63.24% |
| Klaria Pharma Holding AB (publ.) | -35.78 Million SEK | 56.95% |
| Moberg Pharma AB (publ) | -21.09 Million SEK | 26.966% |
| Nanexa AB (publ) | -76.39 Million SEK | 79.836% |
| ODI Pharma AB | 355.97 Thousand SEK | 4427.6% |
| Orexo AB (publ) | -128.3 Million SEK | 87.993% |
| Probi AB (publ) | 16.81 Million SEK | 191.593% |
| Swedencare AB (publ) | 58.6 Million SEK | 126.288% |
| Swedish Orphan Biovitrum AB (publ) | 2.4 Billion SEK | 100.639% |
| Toleranzia AB | -7.45 Million SEK | -106.529% |
| Vivesto AB | -367.03 Million SEK | 95.803% |